Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient

International Clinical Psychopharmacology
George N PapadimitriouConstantin R Soldatos

Abstract

The introduction of atypical antipsychotics into clinical practice has lead to an increase of adverse metabolic effects in psychotic patients. Amisulpride is a substituted benzamide derivative, and its use is associated with a lower risk of weight gain compared to other atypical antipsychotics. The case of an acute and excessive weight increase in a female first-episode schizophrenic patient who was treated with amisulpride monotherapy is reported. The improvement in psychopathology was remarkable. However, the patient gained 12.9 kg of body weight in the first 2 months of amisulpride administration and a total of 17.3 kg, 6 months after initiation of the treatment. Glucose and insulin levels, as well as a glucose tolerance test, remained normal throughout the observation period.

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jul 15, 1999·Psychological Medicine·S BrownC Thompson
Sep 1, 1999·International Clinical Psychopharmacology·C Coulouvrat, L Dondey-Nouvel
Jun 27, 2000·Acta Psychiatrica Scandinavica·D M Taylor, R McAskill
Oct 14, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·P CarrièreT Lempérière
Jan 25, 2002·International Clinical Psychopharmacology·P SaleemH Loo
May 15, 2002·Journal of Clinical Psychopharmacology·Pál CzoborJeffrey A Lieberman
Jul 20, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J PeuskensA Puech
Nov 5, 2002·Schizophrenia Research·Herbert Y MeltzerKaruna Jayathilake
Dec 5, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Daniel SechterUNKNOWN Amisulpride Study Group
Jan 25, 2003·Journal of Clinical Psychopharmacology·Cristóbal GastóMiquel Rodamilans
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Jul 2, 2003·Journal of Clinical Psychopharmacology·Norman Sussman
Dec 3, 2003·Psychopharmacology·Stefan LeuchtWerner Kissling
Jan 30, 2004·Diabetes Care·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Apr 13, 2004·International Clinical Psychopharmacology·Ann MortimerUNKNOWN SOLIANOL Sudy Group
Nov 4, 2004·CNS Drugs·Kate McKeage, Greg L Plosker

❮ Previous
Next ❯

Citations

Sep 20, 2006·Pharmacogenomics·Daniel J Müller, James L Kennedy
Jan 17, 2007·Journal of Clinical Psychopharmacology·Carolin Opgen-RheinMichael Dettling
Oct 6, 2007·Wiener medizinische Wochenschrift·Andreas BaranyiHans-Bernd Rothenhäusler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Related Papers

Psychiatric Services : a Journal of the American Psychiatric Association
Yelena VaninaSteven Lippmann
The Journal of Clinical Psychiatry
J KaneJohn W Newcomer
Diabetes Care
American Diabetes AssociationNorth American Association for the Study of Obesity
© 2021 Meta ULC. All rights reserved